Updated 08:09 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,859.70 -0.68% CL 88.67 +0.12% BTC 64,634.95 -1.03%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,860 −0.68% BTC $64,635 −1.03% VIX 19.30 +3.21% latest tape · as of 08:09 UTC
The Screen · Basic Materials · Chemicals

ASP Isotopes Inc.

ASPI · Nasdaq · USD · Market cap $400M · 271 employees

ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States.

FAIL · Does not pass the screen
1.74 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price1.74 USD at the 13 Nov 2026 close
  • Fair valueUnder review: its inputs are 11 days old; the analyst targets sit too far from the price to cross-check it; our model's value is 7.47x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.65)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders insiders sold, $47,808, latest filing 2026-10-16
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.65, read 2026-11-13
  • Ethical does not pass the values gate
Price1.74 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-09-24Read Markdown3.18-45.3% to today ✓Accumulation gives way to Markdown after an 18% slide in 5 weeks
2026-08-22Read Accumulation3.88-55.1% to today Markup gives way to Accumulation after a 41% slide in 7 weeks
2026-07-02Read Markup6.55-73.4% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

ASP Isotopes Inc. holds its Distribution at $1.74. The statistical read favours the sellers, held for 67 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateThe statistical read favours the sellers, held for 67 days
Price at the screen$1.74
ValuationN/A trailing · -3.35 forward price to earnings
Values screenFAIL · score 70.0
Beta3.52
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 43.36% Below 33% Interest-bearing debt is 43.4% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 9.59% Below 33% Cash held in interest-bearing accounts and securities is 9.6% of assets, under the one-third limit. Pass
Receivables 60.93% Below 49% Money owed to the company is 60.9% of assets, above the 49% limit. Fail
Revenue purity 28.47% Below 5% 28.5% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

ASP Isotopes's business is in a permissible area, but its interest-bearing debt is about 43% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ASPI's ethical verdict changes

Today ASPI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Its inputs are 11 days old; the analyst targets sit too far from the price to cross-check it; our model's value is 7.47x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
11.00Street low 13.00Street average 15.00Street high 1.74Price

Third-party analyst targets. The average target sits +647% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-3.4x
EPS, trailing-2.21
EPS, forward-1.16
Revenue growth+279.3%growing very fast
Profit margin0.0%currently unprofitable
Return on equity-103.3%not currently earning a positive return on equity
FCF yield-8.16%
Debt to equity0.88moderate, manageable leverage
Current ratio4.39comfortably covers its short-term bills
Beta3.52much more volatile than the market
Short interest, float0.21%
52-week range3.61 - 14.49
Market cap$400M
Employees271

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ASPI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-10 Markdown $2.14 +5.9% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-11-03 Markdown $2.02 -8.6% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-10-27 Markdown $2.21 +0.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-10-20 Markdown $2.21 -16.6% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-10-13 Markdown $2.65 -16.7% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-10-02 Markdown $3.18 +0.0% Entry 7

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13. Insiders have been net buyers over the past quarter.

2026-09-24 Markdown · changed $3.18 -17.9% Entry 6

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13.

2026-08-22 Accumulation · changed $3.88 +0.0% Entry 5

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13.

2026-07-22 Markup $3.88 -40.8% Entry 4

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 40.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13.

2026-07-18 Markup $6.55 +0.0% Entry 3

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 32%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (3 analysts) rates it strong buy, with a mean price target of $13.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in ASPI's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · ASPI
DateInsiderTitleTypeSharesValue
2026-10-16 Kiessling Heather CFO S - Sale 21,830 $47,808
2026-10-14 Ainscow Robert COO S - Sale 22,500 $47,565
2026-09-30 Ryan Robert John Andrew Dir P - Purchase 15,000 $40,200
2026-09-28 Ryan Robert John Andrew Dir P - Purchase 8,000 $21,600

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $6.22 -5.5% · $945 -5.5%
2 months $4.48 +31.3% · $1,313 +31.3%
3 months $5.85 +0.5% · $1,005 +0.5%
6 months $6.46 -9.0% · $910 -9.0%
1 year $8.71 -32.5% · $675 -32.5%
2 years $3.99 +47.4% · $1,474 +47.4%
3 years $0.43 +1,283.6% · $13,836 +1,283.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ASPI does next, these words stay.

ASP Isotopes Inc. · ASPI · Distribution · $1.74
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.